Biocon Biologics Limited Eyes IPO In Next 12 Months Biocon Limited Plans To List It's Biosimilars Business By March 2026, Says Shreehas Tambe, MD & CEO Biocon Biologics Limited The Company is Set To Launch 5 New Biosimilars in the US, In Early FY26 In The Segments Of Diabetes, Oncology And Immunotherapy Biosimilars Are Similar And Affordable Versions Of High-Priced And Complex Biologics Drugs Used To Treat Illnesses Like Cancer And Auto-Immune Diseases Biocon Biologics Had Aquired Viatris Inc.'s Global Biosimilars Business For $3.35 Bn Which Included Cash Consideration Of $2 Bn And $ 1 Bn in Stock At Upper Cap Valuation Of $7.6 Bn Of BBL And Rest $335 Mn In Deferred Consideration The Combined Entity Is India's Largest Biopharma Firm And One Of The Largest Standalone Biosimilars Business And As Per Few Unverified Reports, One Of The Top Three Biosimilars Business Globally In 2023, Poonawala Group's Serum Institute Had Invested $300 Mn At $6 Bn Valuation, Making The Investment One Of The Largest Deals In The Space FY24 Revenue : 8,824 Cr EBITDA : 2,190 Cr Till Q3 FY25 Revenue : 6,554 Cr EBITDA : ~1800 Cr Biocon Biologics' IPO Size Should Ideally Be Upwards Of $1 Bn And Might Range Upto $2 Bn, Making It One Of The Largest Public Offerings in India The Company Is One Of A Kind, It Has Significant Market Share Globally And Operations In 120+ Countries, This IPO Should Attract Significant Investor Interest Not Only in India But Globally Excited For This IPO !!